The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Analysis of microtubule-associated protein tau glycation in paired helical filaments.
Open accessAbstract
Alzheimer's disease is typified by the characteristic histopathological lesions of neurofibrillar plaques and tangles. The latter are composed of paired helical filaments (PHFs), the major components of which are modified forms of the microtubule-associated protein tau. The exact nature of these modifications remains unknown, although the presence of hyperphosphorylated tau in PHFs argues strongly that phosphorylation is one of the modifications that result in the polymerization of tau into PHFs. However, hyperphosphorylation alone is insufficient to explain the formation of PHFs. In an attempt to characterize other post-translational modifications of PHF-tau, we have analyzed its glycation. A fraction of PHF-tau seems to be glycated in vivo, whereas soluble tau from either Alzheimer's disease or non-demented human brain is not glycated at all. Purified tau from bovine brain can be efficiently glycated in vitro. Tau glycation is accompanied by a decrease in the tau binding to tubulin. These results support the view that glycation may be one of the modifications hampering the binding of tau to tubulin in Alzheimer's disease, thus facilitating tau aggregation into PHFs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tau is preferentially glycated at Lys residues within the microtubule-binding domain, where advanced glycation end products are generated [177–179].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [177]
Experimental — accuracy not yet measuredIn the citing paper
“Glycated tau is only detected in PHF-tau isolated from AD brain samples, but not in soluble tau from AD or normal brain samples [177, 179].”
From Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease (2020) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Towbin, H., Staehelin, T., & Gordon, J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.9.4350 · Cited by 53,218
Measurement of protein using bicinchoninic acid
Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., & Klenk, D. C. (1985) · Analytical Biochemistry · doi:10.1016/0003-2697(85)90442-7 · Cited by 18,482
Schägger, H., & von Jagow, G. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90587-2 · Cited by 11,420
Electrophoretic analysis of the major polypeptides of the human erythrocyte membrane
Fairbanks, G., Steck, T. L., & Wallach, D. F. H. (1971) · Biochemistry · doi:10.1021/bi00789a030 · Cited by 8,526
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments.
Grundke, I., Iqbal, K., Quinlan, M., Tung, Y. C., Zaidi, M. S., & Wisniewski, H. M. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38495-8 · Cited by 1,780
Kosik, K. S., Joachim, C. L., & Selkoe, D. J. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.11.4044 · Cited by 1,491
Research works printed but not linked: 3
- Greenberg, 1990, Proc. Natl. Acad. Sci. U. S. A., 87, 5825
- Himmler, 1989, Mol. Cell. Biol., 9, 1389
- Maillard, 1912, C. R. Acad. Sci., 154, 66
Cited by
Sorted by citations
Widespread Peroxynitrite-Mediated Damage in Alzheimer’s Disease
Smith, M. A., Richey Harris, P. L., Sayre, L. M., Beckman, J. S., & Perry, G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02653.1997 · Cited by 1,239
“For example, advanced glycation end products (AGE), lipid peroxidation adducts, and free carbonyls are detected in both neurofibrillary tangles (NFTs) and senile plaques (Ledesma et al., 1994; Smith et al., 1994, 1996a; Vitek et al., 1994; Yan et al., 1994; Sayre et al., 1997).”
BackgroundTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease
Guo, T., Zhang, D., Zeng, Y., Huang, T. Y., Xu, H., & Zhao, Y. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00391-7 · Cited by 994
Sayre, L., Zelasko, D. A., Harris, P. L. R., Perry, G., Salomon, R. G., & Smith, M. A. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.68052092.x · Cited by 1,032
Role of tau protein in both physiological and pathological conditions
AVILA, J., LUCAS, J. J., PÉREZ, M., & HERNÁNDEZ, F. (2004) · Physiological Reviews · doi:10.1152/physrev.00024.2003 · Cited by 1,005
“Tau isolated from PHF is glycated (175, 303), and this glycation might be involved in the aggregation of PHF into more complex aggregates (neurofibrillary tangles) (174).”
BackgroundAlonso, A. D. C., Zaidi, T., Novak, M., Grundke-Iqbal, I., & Iqbal, K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121119298 · Cited by 827
Morris, M., Maeda, S., Vossel, K., & Mucke, L. (2011) · Neuron · doi:10.1016/j.neuron.2011.04.009 · Cited by 899
Oxidative stress in Alzheimer’s disease
Smith, M. A., Rottkamp, C. A., Nunomura, A., Raina, A. K., & Perry, G. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00040-5 · Cited by 895
Oxidative Stress and Neurotoxicity
Sayre, L. M., Perry, G. L., & Smith, M. A. (2007) · Chemical Research in Toxicology · doi:10.1021/tx700210j · Cited by 884
Biochemistry and Cell Biology of Tau Protein in Neurofibrillary DegenerationPreprint
Mandelkow, E., & Mandelkow, E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006247 · Cited by 897
“One is glycation by AGEs (advanced glycation end products); this decreases MT binding, promotes aggregation, activates RAGE receptors and thus causes oxidative damage (Ledesma et al. 1994).”
BackgroundTau and neurodegenerative disease: the story so far
Iqbal, K., Liu, F., & Gong, C.-X. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.225 · Cited by 806
Chaudhuri, J., Bains, Y., Guha, S., Kahn, A., Hall, D., Bose, N., Gugliucci, A., & Kapahi, P. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.08.014 · Cited by 669
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Post-translational modifications of tau protein: Implications for Alzheimer's disease
Martin, L., Latypova, X., & Terro, F. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2010.12.023 · Cited by 683
“Tau truncation in AD might later cause glycation (Ledesma et al., 1994) and ubiquitination (Morishima-Kawashima et al., 1993; Perry et al., 1987).”
Type 2 diabetes mellitus, cognitive impairment and dementia
Stewart, R., & Liolitsa, D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00027.x · Cited by 562
Deibel, M. A., Ehmann, W. D., & Markesbery, W. R. (1996) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)00203-1 · Cited by 540
In Situ Oxidative Catalysis by Neurofibrillary Tangles and Senile Plaques in Alzheimer’s Disease
Sayre, L. M., Perry, G. L., Harris, P. L. R., Liu, Y. A., Schubert, K. A., & Smith, M. A. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740270.x · Cited by 543
Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease
Srikanth, V., Maczurek, A., Phan, T., Steele, M., Westcott, B., Juskiw, D., & Münch, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.016 · Cited by 524
Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI
den Heijer, T., Vermeer, S. E., van Dijk, E. J., Prins, N. D., Koudstaal, P. J., Albert Hofman, D., & Breteler, M. M. B. (2003) · Diabetologia · doi:10.1007/s00125-003-1235-0 · Cited by 512
Protein oxidation in the brain in Alzheimer's disease
Aksenov, M. Y., Aksenova, M. V., Butterfield, D. A., Geddes, J. W., & Markesbery, W. R. (2001) · Neuroscience · doi:10.1016/s0306-4522(00)00580-7 · Cited by 505
“Ledesma et al.(24) demonstrated the presence of AGEs in tau in a fraction of PHF in AD, whereas soluble tau from either AD or non-”
BackgroundOxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View
Cenini, G., Lloret, A., & Cascella, R. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/2105607 · Cited by 521
“Several papers published in the early nineties suggested an important role of glycation in the formation of neurofibrillary tangles and senile plaques [103, 104].”
BackgroundHow does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
Radical AGEing in Alzheimer's disease
Smith, M. A., Sayre, L. M., Monnier, V. M., & Perry, G. L. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93897-7 · Cited by 462
Billingsley, M. L., & Kincaid, R. L. (1997) · Biochemical Journal · doi:10.1042/bj3230577 · Cited by 466
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
Elevated 4-Hydroxynonenal in Ventricular Fluid in Alzheimer’s Disease
Lovell, M. A., Ehmann, W. D., Mattson, M. P., & Markesbery, W. R. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00108-5 · Cited by 415
Advanced Glycation End Products in Alzheimer's Disease and Other Neurodegenerative Diseases
Sasaki, N., Fukatsu, R., Tsuzuki, K., Hayashi, Y., Yoshida, T., Fujii, N., Koike, T., WAKAYAMA, I., Yanagihara, R. T., Garruto, R. M., et al. (1998) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65659-3 · Cited by 411
Yan, S. D., Yan, S. F., Chen, X., Fu, J., Chen, M., Kuppusamy, P., Smith, M. A., Perry, G., Godman, G. C., Nawroth, P., et al. (1995) · Nature Medicine · doi:10.1038/nm0795-693 · Cited by 406
Tau Protein Modifications and Interactions: Their Role in Function and Dysfunction
Mietelska‐Porowska, A., Wasik, U., Goras, M., Filipek, A., & Niewiadomska, G. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034671 · Cited by 431
“It is modified by serine, threonine and tyrosine phosphorylation [63], isomerization [64], glycation [65], nitration [66], O-GlcNAcylation [67], acetylation [68], oxidation [69], polyamination [70], sumoylation [71], ubiquitination [72] and proteolytic cleavage (truncation) [73].”
BackgroundFriedhoff, P., Schneider, A., Mandelkow, E., & Mandelkow�, E. (1998) · Biochemistry · doi:10.1021/bi980537d · Cited by 401
Microtubule-associated protein tau in development, degeneration and protection of neurons
Wang, J., & Liu, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.002 · Cited by 405
Du Yan, S., Fu, J., Soto, C., Chen, X., Zhu, H., Al-Mohanna, F., Collison, K., Zhu, A., Stern, E., Saido, T., et al. (1997) · Nature · doi:10.1038/39522 · Cited by 379
Oxidative injury in diseases of the central nervous system: focus on alzheimer’s disease
Praticò, D., & Delanty, N. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00547-7 · Cited by 382
Hanger, D. P., Betts, J. C., Loviny, T. L. F., Blackstock, W. P., & Anderton, B. H. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062465.x · Cited by 386
Common pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
“AGEs are involved in the production of the pathologic hallmarks of AD: accumulation of Aβ is increased by Aβ glycation, and formation of NFTs from phosphorylated tau is accelerated by glycation of tau protein (Ledesma et al., 1994).”
BackgroundOxidative Stress and Neurodegeneration
Moreira, P. I., Smith, M. A., Zhu, X., Nunomura, A., Castellani, R. J., & Perry, G. L. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1333.062 · Cited by 370
The Microtubule-associated Protein Tau Is Extensively Modified with O-linked N-acetylglucosamine
Arnold, C. S., Johnson, G. W., Cole, R. N., Dong, D. L.-Y., Lee, M., & Hart, G. W. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.46.28741 · Cited by 361
Wang, J.-Z., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0896-871 · Cited by 360
(1997) · Europe PMC (PubMed Central) · Cited by 354
Yamamoto, A., Shin, R., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., & Kitamoto, T. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.t01-1-01061.x · Cited by 313
Advanced glycation: an important pathological event in diabetic and age related ocular disease
Stitt, A. W. (2001) · British Journal of Ophthalmology · doi:10.1136/bjo.85.6.746 · Cited by 305
Münch, G. W., Schinzel, R., Loske, C., Wong, A. O., Durany, N., Li, J. J., Vlassara, H., Smith, M. A., Perry, G. L., & Riederer, P. F. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050069 · Cited by 305
“Furthermore, glycated tau found in neurons in AD (Smith et al., 1994b; Yan et al., 1994; Ledesma et al., 1994) causes an oxidative response in neuroblastoma cells including induction of heme oxygenase-1, translocation of NFκB and peroxidation of membrane lipids (Yan et al., 1994, 1995).”
BackgroundPerry, G. L., Nunomura, A., Hirai, K., Zhu, X., Prez, M. D. F., Ávila, J., Castellani, R. J., Atwood, C., Aliev, G., Sayre, L. M., et al. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)01113-9 · Cited by 297
Microtubule-Associated Protein Tau
Yen, S.-H. C., Nacharaju, P., Ko, L., Kenessey, Á., & Liu, W.-K. (1998) · Elsevier eBooks · doi:10.1016/b978-012734610-6/50012-9 · Cited by 284
Giasson, B. I., Ischiropoulos, H., Lee, V. M. ‐., & Trojanowski, J. Q. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00804-3 · Cited by 285
Vitamin E and Alzheimer disease: the basis for additional clinical trials
Grundman, M. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.2.630s · Cited by 269
Yamamoto, A., Shin, R., Hasegawa, K., Naiki, H., Sato, H., YOSHIMASU, F., & Kitamoto, T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01061.x · Cited by 245
Tau phosphorylation in Alzheimer's disease: pathogen or protector?
Lee, H., Perry, G. L., Moreira, P. I., Garrett, M. R., Liu, Q., Zhu, X., Takeda, A., Nunomura, A., & Smith, M. A. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.02.008 · Cited by 253
Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance
Curb, J. D., Rodríguez, B. L., Abbott, R. D., Petrovitch, H., Ross, G. W., Masaki, K., Foley, D. J., Blanchette, P. L., Harris, T. B., Chen, R., et al. (1999) · Neurology · doi:10.1212/wnl.52.5.971 · Cited by 231
Tau Cleavage and Dephosphorylation in Cerebellar Granule Neurons Undergoing Apoptosis
Canu, N., Dus, L., Barbato, C., Ciotti, M. T., Brancolini, C., Rinaldi, A. M., Novak, M., Cattaneo, A., Bradbury, A., & Calissano, P. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-18-07061.1998 · Cited by 232
“…posttranslational changes, including physiological phosphorylation and glycosylation (Lovestone and Reynolds, 1997), as well as pathological phosphorylation (Grundke-Iqbal et al., 1986a), glycosylation (Wang et al., 1996), glycation (Ledesma et al., 1994), and truncation (Novak et al., 1993) in AD.”
BackgroundDemonstrating the case that AD is a vascular disease: epidemiologic evidence
Launer, L. J. (2002) · Ageing Research Reviews · doi:10.1016/s0047-6374(01)00364-5 · Cited by 231
Inhibition of tau phosphorylating protein kinase cdk5 prevents β‐amyloid‐induced neuronal death
Alvarez, A. R., Toro, R., Cáceres, A., & Maccioni, R. B. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01279-x · Cited by 228
Rösler, T. W., Marvian, A. T., Brendel, M., Nykänen, N.-P., Höllerhage, M., Schwarz, S. C., Hopfner, F., Koeglsperger, T., Respondek, G., Schweyer, K., et al. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101644 · Cited by 231
Smith, M. A., Sayre, L. M., Anderson, V. E., Harris, P. L. R., Beal, M. F., Kowall, N. W., & Perry, G. L. (1998) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215549804600605 · Cited by 222
“It is tempting to speculate that neuronal damage involves not only the cytoskeletal proteins that bear glycoxidative (Ledesma et al. 1994; Yan et al. 1995) and lipoxidative (Smith et al., unpublished observation) adducts but also nuclear components.”
BackgroundMontine, K. S., Olson, S. J., Amarnath, K., Whetsell, W. O., Graham, D. G., & Montine, T. J. (1997) · Europe PMC (PubMed Central) · Cited by 220
Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies
Horiguchi, T., Uryu, K., Giasson, B. I., Ischiropoulos, H., Lightfoot, R. T., Bellmann, C., Richter‐Landsberg, C., Lee, V. M. ‐., & Trojanowski, J. Q. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63462-1 · Cited by 220
Lefebvre, T., Ferreira, S., Dupont-Wallois, L., Bussière, T., Dupire, M.-J., Delacourte, A., Michalski, J., & Caillet‐Boudin, M. (2003) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(02)00477-4 · Cited by 209
Updates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 241
“In addition, tau protein in the AD brains undergoes abnormal glycation [416, 417].”
BackgroundMolecular links between Alzheimer’s disease and diabetes mellitus
Yang, Y., & Song, W. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.009 · Cited by 211
Smith, M. A. (1998) · International review of neurobiology · doi:10.1016/s0074-7742(08)60607-8 · Cited by 206
Castellani, R. J., Harris, P. L. R., Sayre, L. M., Fujii, J., Taniguchi, N., Vitek, M. P., Founds, H., Atwood, C., Perry, G. L., & Smith, M. A. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00570-6 · Cited by 198
Neurotoxicity of Advanced Glycation End-Products for Cultured Cortical Neurons
Takeuchi, M., Bucala, R., Suzuki, T., Ohkubo, T., Yamazaki, M., Koike, T., Kameda, Y., & Makita, Z. (2000) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/59.12.1094 · Cited by 198
Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Candeias, E., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2012) · Brain Research · doi:10.1016/j.brainres.2011.12.063 · Cited by 202
Tapia‐Rojas, C., Cabezas-Opazo, F., Deaton, C. A., Vergara, E. H., Johnson, G. V. W., & Quintanilla, R. A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.005 · Cited by 207
“, 1998), indicating that glycated tau likely is more prone to aggregate (Ledesma et al., 1994).”
BackgroundCarbonyl Toxicology and Alzheimer's Disease
Picklo, M. J. (2002) · Toxicology and Applied Pharmacology · doi:10.1006/taap.2002.9506 · Cited by 194
Tau oligomers and aggregation in Alzheimer’s disease
Meraz‐Ríos, M. A., León, K. I. L.-D., Campos‐Peña, V., Anda-Hernández, M. A. D., & Mena‐López, R. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06511.x · Cited by 216
Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease
Perry, G. L., Castellani, R. J., Hirai, K., & Smith, M. A. (1998) · Journal of Alzheimer s Disease · doi:10.3233/jad-1998-1103 · Cited by 184
“Nonetheless, the overall result is damage including advanced glycation end products (53,102,123,126), nitration (29,109), lipid peroxidation adduction products (63,86) as well as carbonyl-modified neurofilament protein and free carbonyls (99,105,107) with the involvement extending beyond the lesions to neurons not dis…”
BackgroundDei, R., Takeda, A., Niwa, H., Li, M., Nakagomi, Y., Watanabe, M., Inagaki, T., Washimi, Y., Yasuda, Y., Horie, K., et al. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0523-y · Cited by 179
Vitamin C and Vitamin E for Alzheimer's Disease
Boothby, L. A., & Doering, P. L. (2005) · Annals of Pharmacotherapy · doi:10.1345/aph.1e495 · Cited by 176
“9 years of treatment and included all of the following: (1) MMSE, (2) animal category, (3) letter fluency, (4) logical memory part 1, (5) logical memory part 2, (6) immediate recall, (7) word list, and (8) digits backwards.”
BackgroundMünch, G. W., Mayer, S., Michaelis, J., Hipkiss, A. R., Riederer, P. F., Müller, R., Neumann, A., Schinzel, R., & Cunningham, A. M. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(96)00062-2 · Cited by 174
Inflammation and NF-κB in Alzheimer's Disease and Diabetes
Granic, I., Dolga, A. M., Nijholt, I. M., van Dijk, G., & Eisel, U. L. M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0976 · Cited by 178
“Furthermore, glycation of A β enhances its aggregation in vitro [75], and glycated tau, in addition to hyperphosphorylation, appears to enhance the formation of paired helical filaments (PHFs) [76,77].”
The sour side of neurodegenerative disorders: the effects of protein glycation
Miranda, H. V., & Outeiro, T. F. (2009) · The Journal of Pathology · doi:10.1002/path.2682 · Cited by 172
“Tau glycation enhances the formation of paired helical filaments in AD and reduces its ability to bind microtubules in vitro [68].”
BackgroundMitochondrial involvement in Alzheimer’s disease
Bonilla, E., Tanji, K., Hirano, M., Vu, T., DiMauro, S., & Schon, E. A. (1999) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00165-0 · Cited by 165
Glycation—a sweet tempter for neuronal death
Kikuchi, S. (2003) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00273-4 · Cited by 169
Chami, L., & Checler, F. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-52 · Cited by 168
AGEs/RAGE complex upregulates BACE1 via NF-κB pathway activation
Guglielmotto, M., Aragno, M., Tamagno, E., Vercellinatto, I., Visentin, S., Medana, C., Catalano, M. G., Smith, M. A., Perry, G. L., Danni, O., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.05.026 · Cited by 163
“The involvement of AGEs in brain aging and in AD was reported more than 10 years ago, in studies that demonstrated that the microtubule associated tau protein as well as A are substrates for glycation (Ledesma et al., 1994; Smith et al., 1994; Vitek et al., 1994; Yan et al., 1994, 1995).”
Amyloidogenesis of Tau protein
Niżyński, B., Dzwolak, W., & Nieznański, K. (2017) · Protein Science · doi:10.1002/pro.3275 · Cited by 166
Alonso, A. D. C., Zaidi, T., Novák, M., Barra, H. S., Grundke, I., & Iqbal, K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105365200 · Cited by 160
Terni, B., Boada, J., Portero‐Otin, M., Pamplona, R., & Ferrer, I. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00266.x · Cited by 159
“Increased levels of glycation end products and lipid peroxidation markers have been observed in brains of patients with AD in association with NFTs and Ab deposits (23, 47, 56).”
BackgroundGrynspan, F., Griffin, W. R., Cataldo, A. M., Katayama, S., & Nixon, R. A. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00384-3 · Cited by 156
Role for glyoxalase I in Alzheimer's disease
Chen, F., Wollmer, M. A., Hoerndli, F. J., Münch, G. W., Kuhla, B., Rogaev, E. I., Tsolaki, M., Papassotiropoulos, A., & Götz, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402338101 · Cited by 151
Litersky, J. M., Johnson, G. V. W., Jakes, R., Goedert, M., Lee, M., & Seubert, P. A. (1996) · Biochemical Journal · doi:10.1042/bj3160655 · Cited by 150
Advanced glycation end products and diabetic complications
Stitt, A. W., Jenkins, A. J., & Cooper, M. E. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.9.1205 · Cited by 152
Smith, M. A., Richey, P. L., Taneda, S., Kutty, R. K., Lm, S., Monnier, V. M., & Perry, G. L. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb21836.x · Cited by 146
Hyperphosphorylated tau proteins differentiate corticobasal degeneration and Pick's disease
Buée‐Scherrer, V., Hof, P. R., Buée, L., Leveugle, B., Vermersch, P., Perl, D. P., Olanow, C. W., & Delacourte, A. (1996) · Acta Neuropathologica · doi:10.1007/s004010050436 · Cited by 150
Yuzwa, S. A., Cheung, A. H., Okon, M., McIntosh, L. P., & Vocadlo, D. J. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2014.01.004 · Cited by 152
“Tau, however, is also subject to a number of other post-translational modifications including, for example, proteolysis [10–12], acetylation [13], glycation [14,15], and O-glycosylation by O-linked N-acetyl-D-glucosamine (O-GlcNAc) [16].”
BackgroundG lycation in P arkinson's disease and Alzheimer's disease
Miranda, H. V., El‐Agnaf, O. M. A., & Outeiro, T. F. (2016) · Movement Disorders · doi:10.1002/mds.26566 · Cited by 146
Role of Hydrogen Peroxide in the Aetiology of Alzheimer??s Disease
Milton, N. G. N. (2004) · Drugs & Aging · doi:10.2165/00002512-200421020-00002 · Cited by 141
Normal and Pathological Tau Proteins as Factors for Microtubule Assembly
Delacourte, A., & Buée, L. (1997) · International review of cytology · doi:10.1016/s0074-7696(08)62588-7 · Cited by 145
Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease
Zana, M., Janka, Z., & Kalman, J. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.03.008 · Cited by 140
Kontaxi, C., Piccardo, P., & Gill, A. C. (2017) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2017.00056 · Cited by 138
“…occurs preferentially at the MBD of PHF-tau (Ledesma and Avila, 1995); lysines present at the R3 repeat were initially identified to be glycated in vitro (Ledesma et al., 1994), but later studies confirmed immunologically that glycation takes place in vivo within the MBD (Ledesma and Avila, 1995).”
BackgroundInfluentialNecula, M., & Kuret, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m405527200 · Cited by 140
Iida, T., Furuta, A., Nishioka, K., Nakabeppu, Y., & Iwaki, T. (2001) · Acta Neuropathologica · doi:10.1007/s004010100418 · Cited by 135
Metal ions and oxidative protein modification in neurological disease.
Sayre, L. M., Moreira, P. I., Smith, M. A., & Perry, G. L. (2005) · PubMed · Cited by 135
Oxidative stress mediates the pathogenic effect of different Alzheimer’s disease risk factors
Guglielmotto, M. (2010) · Frontiers in Aging Neuroscience · doi:10.3389/neuro.24.003.2010 · Cited by 135
“The involvement of AGEs in brain aging and in AD was reported more than 10 years ago, in studies showing that the microtubule associated protein tau and Aβ, were substrates for glycation (Ledesma et al., 1994; Smith et al., 1994; Vitek et al., 1994; Yan et al., 1994, 1995).”
Toxic Advanced Glycation End Products (TAGE) Theory in Alzheimer’s Disease
Sato, T., Shimogaito, N., Wu, X., Kikuchi, S., Yamagishi, S., & Takeuchi, M. (2006) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317506289277 · Cited by 133
Advanced glycation endproducts and their pathogenic roles in neurological disorders
Münch, G. W., Westcott, B., Menini, T., & Gugliucci, A. (2010) · Amino Acids · doi:10.1007/s00726-010-0777-y · Cited by 133
“3) (Ledesma et al. 1994).”
Tauopathy: A common mechanism for neurodegeneration and brain aging
Saha, P., & Sen, N. (2019) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2019.01.007 · Cited by 134
“Prion‐Like” Templated Misfolding in Tauopathies
Clavaguera, F., Lavenir, I., Falcon, B., Frank, S., Goedert, M., & Tolnay, M. (2013) · Brain Pathology · doi:10.1111/bpa.12044 · Cited by 133
“They include tau acetylation (20, 51, 67), glycation (61, 87), O-GlcNAcylation (5), nitration (79), ubiquitination (21, 68), sumoylation (28), prolyl isomerization (65) and truncation (34, 104).”
BackgroundFree radical damage, iron, and Alzheimer's disease
Smith, M. A., & Perry, G. L. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00213-l · Cited by 130
Metadata
- Authors
- Ledesma, M. D., Bonay, P., Colaço, C., & Avila, J.
- Affiliations
- Consejo Superior de Investigaciones Científicas (ES)
- ORCID
- Ledesma, M.D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1994-08
- Volume
- 269
- Issue
- 34
- Pages
- 21614-21619
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W1577069180
- Semantic Scholar
- 68928334bcb2a45f531ceaeaa8ef0e1a72308735
- Cited by
- 333
- References
- 72
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2023: 6 · 2022: 4 · 2021: 8 · 2020: 2 · 2019: 12 · 2018: 13 · 2017: 7 · 2016: 10 · 2015: 5 · 2014: 13 · 2013: 11 · 2012: 13
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Advanced Glycation End Products research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tau protein, glycation, paired helical filaments, Alzheimer's disease, post-translational modification, tau aggregation, neurofibrillary tangles, hyperphosphorylation
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amino Acid Sequence, Animals, Brain Chemistry, Cattle, Diabetes Mellitus, Humans, Lysine, Microtubules, Molecular Sequence Data, Protein Binding, Neurofibrillary Tangles, tau Proteins, Glycation End Products, Advanced, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review